Related Experiment Video
Updated: Mar 25, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
1Clinical Development, R&D Immunoinflammation , GlaxoSmithKline , Collegeville, Pennsylvania , USA.
RMD Open
|February 13, 2016
Summary
Developing biosimilar products requires careful design to prove similarity and gain regulatory approval. Key challenges include ensuring equivalence in clinical trials, using adalimumab as an example.
Area of Science:
- Biopharmaceutical development
- Regulatory science
- Clinical trial design
Background:
- Biosimilar product development is complex, with potential pitfalls in experimental design and execution.
- Failure to demonstrate equivalence can prevent regulatory approval.
- Regulatory guidance mandates a stepwise approach, starting with structural and functional characterization.
Purpose of the Study:
- To highlight critical design elements for biosimilar development programs.
- To discuss challenges in designing Phase III clinical efficacy studies for biosimilars.
- To use adalimumab as a case study for illustrating design considerations.
Main Methods:
- Review of regulatory guidance for biosimilar development.
- Analysis of a stepwise approach to demonstrating biosimilarity.
- Case study analysis using adalimumab.
Main Results:
- A stepwise approach is crucial, with subsequent study requirements dependent on earlier evidence.
- Clinical efficacy trials are often necessary to confirm comparative safety and effectiveness.
- Phase III study design for biosimilars presents unique challenges due to the focus on similarity.
Conclusions:
- Meticulous experimental design and execution are essential for biosimilar success.
- Careful attention to specific design elements is needed, particularly in pivotal clinical trials.
- Understanding these challenges is key to navigating the regulatory landscape for biosimilar approval.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
01:13Bioequivalence studies: Biowaivers
382
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
382
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
208
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
208
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:16Bioequivalence Data: Statistical Interpretation
319
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
319
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
522
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
522